{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:07:30Z","timestamp":1789560450030,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijantimicag.2013.05.005","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T09:33:10Z","timestamp":1373275990000},"page":"202-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Daptomycin: The role of high-dose and combination therapy for Gram-positive infections"],"prefix":"10.1016","volume":"42","author":[{"given":"Ian M.","family":"Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0005","series-title":"Cubicin\u00ae (daptomycin) summary of product characteristics","author":"Novartis Europharm Ltd.","year":"2012"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0010","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijantimicag.2011.08.007","article-title":"Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections","volume":"39","author":"Quist","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-7-29","article-title":"Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)","volume":"7","author":"Sader","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jac\/dkn439","article-title":"Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"63","author":"Leonard","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/cis492","article-title":"In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates","volume":"55","author":"Saravolatz","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0040","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1128\/AAC.06439-11","article-title":"Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0045","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.47.5.1598-1603.2003","article-title":"Daptomycin dose\u2013effect relationship against resistant Gram-positive organisms","volume":"47","author":"Cha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0055","series-title":"Cubicin (daptomycin) prescribing information","author":"Cubist Pharmaceuticals Inc.","year":"2012"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0060","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0065","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, valid from 2012-01-01. EUCAST; 2012. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_2.0_120221.pdf [accessed 23.10.12]."},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0315","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-first international supplement. Document M100-S21","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0070","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMoa1011138","article-title":"Genetic basis for in vivo daptomycin resistance in enterococci","volume":"365","author":"Arias","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0075","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/jac\/dkr195","article-title":"Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach","volume":"66","author":"Fischer","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0080","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal \u03b2-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0090","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Mir\u00f3","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0095","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1128\/AAC.05551-11","article-title":"Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium","volume":"56","author":"Sakoulas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0100","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/AAC.01525-12","article-title":"\u03b2-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jac\/dkh104","article-title":"Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci","volume":"53","author":"Rand","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0110","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1128\/AAC.00141-11","article-title":"Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model","volume":"55","author":"Furustrand","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0115","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1128\/AAC.01455-06","article-title":"Activity of daptomycin alone and in combination with rifampicin and gentimicin against Staphylococcus aureus assessed by time\u2013kill methodology","volume":"51","author":"Credito","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0120","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/AAC.01185-12","volume":"56","author":"Steed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0125","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1128\/AAC.01046-12","article-title":"Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim\u2013sulfamethoxazole","volume":"56","author":"Avery","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0130","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1128\/AAC.00675-11","article-title":"Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus","volume":"55","author":"Saleh-Mghir","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0135","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1128\/AAC.00226-10","article-title":"Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"54","author":"Garrigos","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0140","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.00455-10","article-title":"Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm","volume":"54","author":"Parra-Ruiz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0145","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1128\/AAC.01921-12","article-title":"Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group streptococci after exposure to daptomycin","volume":"57","author":"Garc\u00eda-de-la-M\u00e0ria","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijantimicag.2011.03.006","article-title":"Daptomycin: evaluation of a high-dose treatment strategy","volume":"38","author":"Wu","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0155","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/jac\/dkp346","article-title":"Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies","volume":"64","author":"Steenbergen","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","article-title":"Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997\u20132002)","volume":"50","author":"Biedenbach","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2013.05.005_bib0170","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0175","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-010-1128-3","article-title":"Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient\u2014a review of the literature","volume":"30","author":"van Hal","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0180","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0185","series-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Comparison of high dose daptomycin (DAP) and dose optimized vancomycin (VAN) for MRSA bacteremia and infective endocarditis (IE)","author":"Davis","year":"2012"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0190","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0195","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","article-title":"High-dose daptomycin in documented Staphylococcus aureus infections","volume":"36","author":"Bassetti","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0200","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0205","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","article-title":"Safety and clinical outcomes when utilizing high-dose (\u22658mg\/kg) daptomycin therapy","volume":"43","author":"Moise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0210","series-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Daptomycin for treatment of enterococcal infections: multicenter, retrospective study","author":"Casapao","year":"2012"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0215","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.02192-12","article-title":"Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant \u03b2-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment","volume":"57","author":"Moise","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(03)15266-X","article-title":"Infective endocarditis","volume":"363","author":"Moreillon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0225","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0230","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/hrt.2008.152975","article-title":"Coagulase-negative staphylococcal prosthetic valve endocarditis\u2014a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study","volume":"95","author":"Chu","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0235","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1378\/chest.124.4.1451","article-title":"Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome","volume":"124","author":"del R\u00edo","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0240","first-page":"187","article-title":"Erythromycin and penicillin resistance mechanisms among viridans group streptococci isolated from blood cultures of adult patients with underlying diseases","volume":"34","author":"Ergin","year":"2011","journal-title":"New Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0245","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1161\/CIRCULATIONAHA.105.165564","volume":"111","author":"Baddour","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0250","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehp285","article-title":"Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC)","volume":"30","author":"Habib","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0255","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1128\/AAC.00869-07","article-title":"Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"52","author":"Rose","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0260","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jac\/dkm170","article-title":"Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies","volume":"60","author":"Rose","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0265","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.01307-08","article-title":"Relationship between susceptibility to daptomycin in vitro and activity in vivo in the rabbit model of aortic valve endocarditis","volume":"53","author":"Chambers","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0270","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1128\/AAC.36.12.2611","article-title":"Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium","volume":"36","author":"Caron","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0275","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1128\/AAC.01608-12","article-title":"Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis","volume":"57","author":"Tascini","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0280","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2334-11-152","article-title":"High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0285","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijantimicag.2009.08.019","article-title":"High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides","volume":"35","author":"Lichterfeld","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0290","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.01011-09","article-title":"Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis","volume":"54","author":"Garc\u00eda-de-la-M\u00e0ria","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0295","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/cid\/cir805","article-title":"High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis","volume":"54","author":"Durante-Mangoni","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0435","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0300","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1345\/aph.1M324","article-title":"Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin","volume":"43","author":"Schutt","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0305","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1099\/jmm.0.47331-0","article-title":"Biofilm formation by enterococci","volume":"56","author":"Mohamed","year":"2007","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1086\/346153","article-title":"Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins","volume":"36","author":"Lautenbach","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0320","series-title":"21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Evaluation of safety and tolerability of daptomycin doses >=8mg\/kg\/day: results from 270 patients in the European Cubicin\u00ae Outcomes Registry and Experience (EU-CORESM)","author":"Utili","year":"2011"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2013.05.005_bib0325","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1093\/jac\/dkh202","article-title":"Complicated infections of skin and skin structures: when the infection is more than skin deep","volume":"53","author":"DiNubile","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0330","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/656431","article-title":"Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship","volume":"51","author":"Jenkins","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0335","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijantimicag.2004.06.004","article-title":"Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison","volume":"24","author":"Esposito","year":"2004","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2013.05.005_bib0340","doi-asserted-by":"crossref","first-page":"iii15","DOI":"10.1093\/jac\/dkn368","article-title":"Daptomycin: rationale and role in the management of skin and soft tissue infections","volume":"62","author":"Seaton","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0345","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1742-1241.2008.01854.x","article-title":"A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria","volume":"62","author":"Katz","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0350","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0355","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1128\/AAC.00047-09","article-title":"Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: the importance of combination with rifampin","volume":"53","author":"John","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0360","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/AAC.01570-12","article-title":"Fosfomycin\u2013daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"57","author":"Garrigos","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0365","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1093\/jac\/dks272","article-title":"Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm","volume":"67","author":"Parra-Ruiz","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0370","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1128\/AAC.00208-09","article-title":"Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"53","author":"Murillo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0375","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1179\/joc.2009.21.4.414","article-title":"Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry","volume":"21","author":"Crompton","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0380","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkt067","article-title":"Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database","author":"Seaton","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0385","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dks119","article-title":"Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections","volume":"67","author":"Corona P\u00e9rez-Cardona","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0390","series-title":"20th European Congress of Clinical Microbiology and Infectious Diseases","first-page":"S343","article-title":"Efficacy and safety of high-dose daptomycin in Staphylococcus aureus infections","author":"Bassetti","year":"2010"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0395","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0400","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Once-daily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0405","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for Gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0410","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0415","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0420","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s10096-011-1500-y","article-title":"Safety analysis of high dose (>6mg\/kg\/day) daptomycin in patients with concomitant statin therapy","volume":"31","author":"Parra-Ruiz","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0425","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dki422","article-title":"Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function","volume":"57","author":"Huang","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.005_bib0430","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.02000-12","article-title":"Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis","volume":"57","author":"Butterfield","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T11:28:19Z","timestamp":1563362899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0924857913001830"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.05.005","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daptomycin: The role of high-dose and combination therapy for Gram-positive infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}